Federal Cannabis Rescheduling: What It Means for Vermont Medical Patients and Dispensaries

For more than 50 years, cannabis sat alongside heroin and LSD on Schedule I of the Controlled Substances Act — a classification reserved for substances with "no accepted medical use and a high potential for abuse." On April 23, 2026, Acting U.S. Attorney General Todd Blanche signed an order changing that — at least for state-legal medical cannabis.

Under the new order, cannabis dispensed through state-licensed medical programs, including Vermont's, moves to Schedule III. Recreational cannabis sold at adult-use dispensaries remains Schedule I. It is the first federal reclassification of cannabis since the Controlled Substances Act was enacted in 1970, and it has significant implications for Vermont's medical cannabis market specifically.

What Schedule III actually means

Schedule III substances are recognized by the federal government as having "a currently accepted medical use" and carrying "moderate to low potential for dependence." The category includes anabolic steroids, ketamine (the anesthetic and fast-acting antidepressant), and buprenorphine used for opioid-use disorder treatment. Moving from Schedule I to Schedule III means the federal government formally acknowledges that medical cannabis has legitimate therapeutic applications.

What it does not do: it does not legalize recreational cannabis at the federal level, does not invalidate state-level drug laws, and does not immediately override any existing business regulations. The DEA still has enforcement authority, and state-licensed businesses must apply for DEA registration through an expedited process under the new order.

Why only medical — and why it happened so fast

The split between medical and recreational is a direct consequence of the legal path the DOJ used. Blanche invoked Section 811(d)(1) of the Controlled Substances Act, a treaty-compliance pathway that lets the Attorney General place a substance in whatever schedule is needed to meet U.S. obligations under the 1961 Single Convention on Narcotic Drugs. That pathway allowed immediate rescheduling without the years-long notice-and-comment rulemaking and evidentiary hearings the normal process (CSA Sections 811(a) and (b)) requires — but it reaches only cannabis that is "included in an FDA-approved drug product or subject to a state-issued license to manufacture, distribute, and/or dispense marijuana for medical purposes." Everything else, including all adult-use recreational cannabis, stays in Schedule I alongside heroin.

The same April 23 order also restarted the clock on the broader question. Blanche directed the DEA to open an expedited administrative hearing — scheduled to begin June 29, 2026 — to consider rescheduling all marijuana from Schedule I to Schedule III. That hearing, not the April order, is the route by which recreational cannabis could eventually move. It has not concluded, and any change for adult-use cannabis is still hypothetical.

The order is being challenged in court. Smart Approaches to Marijuana (SAM) and the National Doctors Alliance for Cannabis Safety asked a federal court to stay it, arguing that the treaty pathway was improperly invoked and that the order violates the Administrative Procedure Act and exceeds the Attorney General's statutory authority. In early June 2026, a coalition of Republican-led states filed a separate lawsuit seeking to overturn the rescheduling. As of this writing the order remains in effect, but the litigation is unresolved.

The tax change that matters most: goodbye to Section 280E (for medical)

The most immediate real-world impact of rescheduling is on federal taxes — specifically, the end of Section 280E exposure for state-legal medical cannabis operations.

Section 280E of the Internal Revenue Code prohibits businesses that traffic in controlled substances listed under Schedule I or II from deducting ordinary business expenses. Every other legal business in America can deduct wages, rent, utilities, insurance, and marketing costs from taxable revenue. Cannabis operators could not — because their product was Schedule I. They paid federal income taxes on gross revenue rather than net profit, producing effective tax rates of 70% to 90% or more. A mid-sized Vermont dispensary paying 80% in effective federal taxes while a standard retail business paid 21% was not a competitive market — it was a tax penalty for being a state-licensed, regulated operator rather than an illicit one.

Schedule III substances are not covered by 280E. With medical cannabis now at Schedule III, dispensaries that operate licensed medical cannabis programs may deduct the same expenses any other business deducts: non-production employee wages, rent, utilities, insurance premiums, marketing costs, and legal fees. The tax math flips dramatically — potentially down toward the standard 21% corporate rate on net profits rather than effective 70–90% rates on gross revenue.

Compass Vermont, a Vermont business publication, summarized it plainly: "From 80% tax rates to 21%." For Vermont medical cannabis operators, that is a real and significant financial change — if and when the IRS finalizes its implementation guidance.

Vermont's medical market: the specific opportunity

Vermont has operated a medical cannabis program since 2004, one of the longer-running in the country. Vermont's 2025 cannabis sales exceeded $150 million, and the state's medical and recreational markets are deeply intertwined — most Vermont dispensaries hold dual licenses and serve both registered patients and adult-use customers.

Gabe Gilman, general counsel for Vermont's Cannabis Control Board, told VTDigger that rescheduling could "turbocharge" Vermont's medical market. The logic: if medical operations receive favorable tax treatment that recreational sales still do not, there is a strong incentive for dispensaries to expand and invest in their medical programs — better patient services, dedicated medical staff, specialized product lines for chronic conditions, and pricing calibrated for regular patients rather than occasional recreational buyers.

Joseph Verga, who operates Green Leaf Central in Burlington, called the tax change "a huge win" — while adding a note of realistic caution: "I'll believe it when I see it." That skepticism is warranted. Federal cannabis policy has a long history of promising change without clean implementation.

For medical patients specifically, the downstream effect of a 280E end could include lower product prices as dispensaries pass some of their tax savings through to the shelf. It could also fund investment in the budtender training for medical patients that Vermont's CCB has already begun requiring (Act 56, 2025). And expanded federal research access — a consequence of Schedule III's recognized-medical-use status — could produce better clinical data on dosing, drug interactions, and efficacy that patient-facing dispensaries could actually use.

Vermont's medical registry includes patients whose conditions include chronic pain (cited by roughly 60% of registrants), PTSD, cancer, multiple sclerosis, HIV/AIDS, and other qualifying conditions. Those patients stand to benefit most from a medical market that is better capitalized and more focused.

What's still uncertain — and it's a lot

Vermont cannabis operators and patients should not expect immediate price drops or sudden changes at the counter. Several large uncertainties remain as of June 2026:

IRS guidance is still pending. The Treasury Department and IRS have announced they will issue guidance on what qualifies as a "medical cannabis business" eligible for 280E relief. Until that guidance lands, dispensaries face real legal uncertainty about what they can deduct, which tax years are affected, and how to document medical versus recreational revenue. Most operators are keeping close counsel with their tax attorneys before changing how they file.

DEA registration requirements are unclear. The rescheduling order says state-licensed medical cannabis businesses can apply for DEA registration through an expedited process. What that process looks like in practice — forms, fees, inspections, timelines — has not yet been defined. Businesses that fail to register correctly could lose their Schedule III status for tax purposes.

Litigation is ongoing. SAM and allied physician groups have asked a federal court to stay the order, and a coalition of Republican-led states sued in early June 2026 to overturn it — both arguing the §811(d)(1) treaty pathway was misused. The outcome is not certain. Vermont operators in particular, having watched federal cannabis policy shift under successive administrations, are watching the court dockets carefully.

The broader rescheduling hearing is just starting. The expedited DEA hearing on moving all cannabis — including recreational — to Schedule III is set to begin June 29, 2026. Its result is unknown and could take many months. Until then, the medical-only split, and the 280E divide between medical and recreational revenue, stays in place.

280E relief is not retroactive. The IRS has confirmed that any 280E relief applies going forward. Businesses cannot file amended returns for prior years' taxes paid under 280E. Outstanding 280E-era tax obligations remain due. For some Vermont dispensaries carrying large legacy tax burdens, this means cash flow pressure even as the forward-looking picture improves.

Recreational sales remain Schedule I. This is the critical distinction many consumers have missed. Adult-use cannabis sold at Vermont dispensaries remains federally Schedule I. The 280E prohibition still applies to revenue attributable to recreational sales. Dual-license dispensaries serving both markets will need clean accounting to separate medical and recreational revenue for tax purposes — a compliance challenge the IRS has not yet defined rules for.

What this means at Burlington-area dispensaries right now

In practical terms for a consumer visiting a Burlington dispensary in June 2026: nothing has changed at the counter. Prices, purchase limits, and checkout procedures are the same. Dispensaries are not yet passing through tax savings because those savings are not yet realized — they exist on paper pending IRS guidance, DEA registration, and resolution of the litigation.

If you hold a Vermont medical cannabis registry card, the most likely near-term effect is that the dispensaries you visit will invest more in their medical programs over the coming year — better staff training, longer budtender consultation time for patients, and potentially expanded medical product categories. Several Burlington-area shops already operate dedicated medical consultation windows or patient intake processes; expect those to deepen.

If you are a recreational consumer with no medical registration, rescheduling does not affect your purchasing experience. Your purchases are still federally Schedule I transactions from the dispensary's perspective. If chronic pain or another qualifying condition is a real factor in your use, this is a reasonable moment to ask a dispensary about the Vermont medical registration process — our Vermont medical cannabis card guide covers the qualification steps, and the cost difference between medical and recreational can be significant.

Watch the Burlington Dispensaries news feed for updates as IRS and DEA guidance materializes. The full directory of Burlington licensed dispensaries lists current hours and contact information. For an overview of Vermont's cannabis legal landscape, the Vermont cannabis guide covers state law, purchase limits, and tax structure.